Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SOL-116
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : QPS Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 12, 2022
Lead Product(s) : SOL-116
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : QPS Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable